Skip to main content
03/01/2024

VHIR participates in a European project to optimise AI and data analytics use in healthcare

Projecte-PHASE_IV_AI

The project's members met in Helsinki.

03/01/2024

Phase IV AI is included in the Horizon Europe programme, lasts 3 years and prioritises data security and privacy compliance.

Vall d’Hebron Institute of Research (VHIR) participated together with another nineteen partners from ten European & Associated countries in a meeting in Helsinki to launch the PHASE-IV-AI project activities and discuss the procedures that the consortium will follow during its implementation period as well as the work to be carried out the upcoming period. The meeting was attended by the Project Officer Ms. Serena Battaglia from the European Health and Digital Executive Agency (HaDEA) of European Commission, as well as, more than 50 experts from leading edge universities and research centres, technology providers as well as prominent end-users from the healthcare sector. On behalf of the VHIR, the main researcher involved in the project is Dr. Manuel Escobar of the Molecular Medical Imaging Research Group. 

Artificial intelligence (AI) enables data-driven innovations in health care. AI systems, which process vast amounts of data quickly and in detail, show promise both as a tool for preventive health care and clinical decision-making. However, the distributed storage and limited access to health data form a barrier to innovation, as developing trustworthy AI systems requires large datasets for training and validation. Furthermore, the availability of anonymous datasets would increase the adoption of AI-powered tools by supporting health technology assessments and education. 

Secure, privacy compliant data utilization is key for unlocking the full potential of AI and data analytics. Companies developing AI solutions would benefit from synthetic microdata for early-stage development, provided on-demand and with privacy guarantees. For researchers and clinicians interested in aggregate data or modelling, multi-party computation allows deriving insights from the distributed real-world data. In this way, providing synthetic data and multi-party computation as a service will boost data-driven innovation without compromising the privacy of data subjects.

The project will be validated with three real life cases

PHASE-IV-AI will advance the current state-of-the-art data synthesis methods towards a more generalized approach of synthetic data generation. PHASE-IV-AI will develop metrics for testing and validation.  Specifically, the developments of PHASE-IV-AI project will be validated in 3 real life use cases in relevant high impact diseases as are Lung Cancer, Prostate Cancer, and Ischemic Stroke. All the three diseases are key topics of the European Health ecosystem. Lung Cancer as well as Prostate Cancer are among the top 3 priorities in tackling cancer, neurodegenerative diseases are one of the most relevant issues with the EU’s ageing population. 

PHASE-IV-AI has six main objectives. First, improve methods and technical pipelines for privacy-preserving data synthesis including different data formats such as Electronic Health Records (EHRs) and medical images. Second, provide easy to use and configurable data services to enable AI developers’ access to larger pools of decentralized de-identified data through multi-party computing. Third, provide anonymous data on demand or from a (temporary) repository. Fourth, establish a Data Market – facilitating data sharing and monetization including incentives-based provision of data to the services. Fifth, integrate the data market and the data service ecosystem as a X-European health data hub in the European Health Data Space. And lastly, validate the results with real-world use-cases focusing on high impact diseases, cancer types in particular.

The PHASE IV AI is a project funded by the European Union’s Horizon Europe research and innovation program under grant agreement number 101095384 with a lifecycle of thirty-six months.

 20 partners from 10 different countries participated in the project

Related news

The team will investigate, in animal models, the benefits of histotripsy, a technique that allows tumors to be destroyed without incision or heat, and hopes to minimize the risks and enhance the efficacy of immunotherapy.

This new technology will be completely harmless for patients, as it does not use radiation, and will offer superior image quality and better monitoring of tumours, among other benefits.

The event, organized by Vall d'Hebron and Eurecat, has brought together health professionals and researchers in clinically applied AI to improve the medical care of patients.

Related professionals

Manuel Escobar Amores

Manuel Escobar Amores

Main researcher
Molecular Medical Imaging
Read more
Susana  Garcia  Bayona

Susana Garcia Bayona

Molecular Medical Imaging
Read more
Alberto Roque Pérez

Alberto Roque Pérez

Molecular Medical Imaging
Read more
Hug Cuellar Calabria

Hug Cuellar Calabria

Senior researcher
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.